A rapid and sensitive High-Performance Liquid Chromatography-tandem Mass Spectrometry method for determining apremilast in beagle dog plasma and urine: Application in a pharmacokinetic study

• Autorzy: Yan Genquan , Yu Lu , Chen Xu , Tran Triet , Nguyen Lam , Zhijun Wang , Wang Ling
• Języki publikacji: EN

Abstrakty

EN

A rapid and sensitive High-Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC/MS/MS) method for determining apremilast in beagle dog plasma and urine samples was developed and validated using clopidogrel as the internal standard (IS). Apremilast was extracted from the plasma and urine samples by liquid–liquid extraction using methyl tert-butyl ether. Chromatographic separation was performed using a C8 column with gradient elution and a mobile phase containing methanol and 0.1% formic acid. Quantification was achieved in multiple reaction monitoring (MRM) mode with a transition of m/z 461.3→178.2 for apremilast and m/z 322.2→184.1 for clopidogrel (IS). This method was validated regarding its specificity, linearity, precision, accuracy, and stability. The lower limit of quantification (LLOQ) for this method was 5 ng/mL, and the calibration curve was linear over 5–1,000 ng/mL. The intra- and inter-run coefficients of variance (CV) of aprelimast in plasma samples were less than 12.92% and 10.64%, respectively, while in urine samples, the CV were less than 11.84% and 10.20%, respectively. The samples were stable under the tested conditions. This method was successfully applied to a pharmacokinetic study in beagle dogs following oral administration of 10 mg of apremilast.

Słowa kluczowe

EN

apremilast; HPLC-MS/MS; pharmacokinetics; urine excretion

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2021
• Tom: Vol. 33, no. 2
• Strony: 112--119
• Opis fizyczny: Bibliogr. 19 poz., rys., tab.

Twórcy

autor

Yan Genquan

• Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, PR China

autor

Yu Lu

• Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, PR China

autor

Chen Xu

• Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, PR China

autor

Tran Triet

• Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA, 92831, USA

autor

Nguyen Lam

• Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA, 92831, USA

autor

Zhijun Wang

• Department of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA, 92831, USA

• https://orcid.org/0000-0001-8783-8946

autor

Wang Ling

• Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, PR China

• https://orcid.org/0000-0003-3220-6065

Bibliografia

• 1. Mahmood, T.; Zaghi, D.; Menter, A. Emerging oral drugs for psoriasis. Expet Opin. Emerg. Drugs 2015, 20(2), 209–20.
• 2. Man, H. W.; Schafer, P.; Wong, L. M.; Patterson, R. T.; Corral, L. G.; Raymon, H.; Blease, K.; Leisten, J.; Shirley, M. A.; Tang, Y.; Babusis, D. M.; Chen, R.; Stirling, D.; Muller, G. W. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J. Med. Chem. 2009, 52(6), 1522–4.
• 3. Lowes, M. A.; Bowcock, A. M.; Krueger, J. G. Pathogenesis and therapy of psoriasis. Nature 2007, 445(7130), 866–73.
• 4. Schafer, P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 2012, 83(12), 1583–90.
• 5. Claveau, D.; Chen, S. L.; O’Keefe, S.; Zaller, D. M.; Styhler, A.; Liu, S.; Huang, Z.; Nicholson, D. W.; Mancini, J. A. Preferential inhibition of T Helper 1, but Not T Helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J. Pharmacol. Exp. Ther. 2004, 310(2), 752–60.
• 6. Eigler, A.; Siegmund, B.; Emmerich, U.; Baumann, K. H.; Hartmann, G.; Endres, S. Anti-inflammatory activities of cAMPelevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukoc. Biol. 1998, 63(1), 101–7.
• 7. Raychaudhuri, S. P.; Raychaudhuri, S. K.; Genovese, M. C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol. Cell. Biochem. 2012, 359(1–2), 419–29.
• 8. Serezani, C. H.; Ballinger, M. N.; Aronoff, D. M.; Peters-Golden, M. Cyclic AMP: master regulator of innate immune cell function. Am. J. Respir. Cell. Mol. Biol. 2008, 39(2), 127–32.
• 9. Uyemura, K.; Yamamura, M.; Fivenson, D. F.; Modlin, R. L.; Nickoloff, B. J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 1993, 101(5), 701–5.
• 10. Kavanaugh, A.; Mease, P. J.; Gomez-Reino, J. J.; Adebajo, A. O.; Wollenhaupt, J.; Gladman, D. D.; Hochfeld, M.; Teng, L. L.; Schett, G.; Lespessailles, E.; Hall, S. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J. Rheumatol. 2015, 42(3), 479–88.
• 11. Kavanaugh, A.; Mease, P. J.; Gomez-Reino, J. J.; Adebajo, A. O.; Wollenhaupt, J.; Gladman, D. D.; Lespessailles, E.; Hall, S.; Hochfeld, M.; Hu, C.; Hough, D.; Stevens, R. M.; Schett, G. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 2014, 73(6), 1020–6.
• 12. Schett, G.; Wollenhaupt, J.; Papp, K.; Joos, R.; Rodrigues, J. F.; Vessey, A. R.; Hu, C.; Stevens, R.; de Vlam, K. L. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis. Rheum. 2012, 64(10), 3156–67.
• 13. Papp, K.; Reich, K.; Leonardi, C. L.; Kircik, L.; Chimenti, S.; Langley, R. G.; Hu, C.; Stevens, R. M.; Day, R. M.; Gordon, K. B.; Korman, N. J.; Griffiths, C. E. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 2015, 73(1), 37–49.
• 14. Sigler, J. Drug updates and approvals: 2014 in review. J. Nurse Pract. 2014, 39(12), 14–23; quiz 23–4.
• 15. Hoffmann, M.; Kumar, G.; Schafer, P.; Cedzik, D.; Capone, L.; Fong, K. L.; Gu, Z.; Heller, D.; Feng, H.; Surapaneni, S.; Laskin, O.; Wu, A. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica 2011, 41(12), 1063–75.
• 16. Liu, Y.; Zhou, S.; Assaf, M.; Nissel, J.; Palmisano, M. Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12. Clin. Pharmacol. Drug Dev. 2016, 5(6), 469–79.
• 17. Liu, Y.; Zhou, S.; Nissel, J.; Wu, A.; Lau, H.; Palmisano, M. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin. Pharmacol. Drug Dev. 2014, 3(6), 456–65.
• 18. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (CVM) Bioanalytical Method Validation Guidance for Industry. 2018.
• 19. Iqbal, M.; Ezzeldin, E.; Al-Rashood, S. T.; Imam, F.; Al-Rashood, K. A. Determination of apremilast in rat plasma by UPLC-MS/MS in ESInegativemode to avoid adduct ions formation. Bioanalysis 2016, 8(14), 1499–508.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).